Investigation of the Value of ctDNA in Diagnosis, Treatment, and Surveillance of Surgically Resectable Colorectal Cancer

Peking Union Medical College Hospital300 enrolled

Overview

In this study, we aim to investigate the value of circulating tumor DNA (ctDNA) analysis in the diagnosis, treatment, and surveillance of patients with surgically resectable colorectal cancer, by performing serial analysis of ctDNA, next-generation sequencing of surgical specimens, and observation of patients undergoing radical resection of the tumor with or without adjuvant chemo- and/or radiotherapy.

A prospective, observational study to determine the value of circulating tumor DNA (ctDNA) for predicting the therapeutic effects of the combined modality treatment for colorectal cancer and the patients' long-term prognosis. Research objects: patients with surgically resectable colorectal cancer. After giving fully informed consent, the prospective participants will undergo the classical combined modality treatment according to NCCN guidelines. Serial analysis of ctDNA will be performed at specific time points including pre-treatment, (post-NCRT for NCRT patients), postoperative week 1, post-ACT, postoperative year 1, 2, and 3. The next-generation sequencing of surgical specimens will be performed as well. Participants will be observed and examined during the entire course of treatment and the follow-up period. The 3 year disease free survival (3y-DFS) will be the primary end-point.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

300

Conditions

Rectal Cancer, Adenocarcinoma Neoadjuvant Chemoradiation

Interventions

Capecitabine +/- OxaliplatinDRUG

Patients in ACT group will undergo postoperative adjuvant chemotherapy with single agent Capecitabine regimen or combined Capecitabine +Oxaliplatin regimen.

local resectionPROCEDURE

Patients in the LR group will undergo local resection of the T1-2N0 rectal carcinoma

radical resectionPROCEDURE

Patients in the RR group will undergo radical resection of the T1-2N0 rectal carcinoma

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients aged 18 to 75 years old. 2. Patients with surgically resectable colorectal cancer, while without distal metastasis of the disease. 3. Patients with ASA physical status scroe of I to III. 4. Patients who can fully understand the content of the informed consent form and sign it upon their own opinions. 5. Patients who can coordinate with the researchers to undergo the long-term post-treatment rechecks and follow-ups. Exclusion Criteria: 1. Patient has any underlying or current medical condition, which, in the opinion of the Investigator, would interfere with the evaluation of the patient (e.g., end-stage liver disease, pulmonary hypertension, systemic lupus erythematosis etc.). 2. Patient is pregnant or lactating. 3. Patient has a history of malignancy within 5 years except curatively treated basal cell carcinoma, squamous cell carcinoma in a non-mucosal, ultraviolet exposed area, or cervical carcinoma. 4. Patient is participating in any other clinical trials within 30 days prior to screening. 5. Patient has severe mental illness. 6. Patient has any other conditions, which, in the opinion of the Investigator, would interfere with the evaluation of the subject.

Outcomes

Primary Outcomes

5y DFS

The 5-year disease free survival rate of the patients.

Time frame: 5 years

5y LR

The 5-year local recurrence rate of the patients.

Time frame: 5 years

5y OS

The 5-year overall survival rate of the patients.

Time frame: 5 years

Secondary Outcomes

Changes of ctDNA level after surgery

Changes of patients' ctDNA level after undergoing surgical resection of the tumor.

Time frame: 1 month

Changes of ctDNA level after adjuvant therapy

Changes of patients' ctDNA level after receiving adjuvant therapy (eg. adjuvant chemothearpy).

Time frame: 6 months

Changes of ctDNA level when disease recurs

Changes of patients' ctDNA level after disease recurrence happens

Time frame: 5 year

Central Contacts

Jiaolin Zhou, MD

CONTACT

8613910136704 conniezhjl@yahoo.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.